Is 18 F-FDG PET/CT Necessary During Vismodegib Therapy for Basal Cell Carcinoma? Quantitative Changes and Incremental Value Beyond CT
Abstract Objectives The role of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in monitoring basal cell carcinoma (BCC) during vismodegib therapy remains poorly defined, particularly in patients with extensive, multifocal, or Gorlin syndrome–associated disease. This study ai...